At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ORPH Orphazyme A/S
Trading 12-10 14:40:20 EST
0.8700
+0.0000
0.00%
High0.8700Low0.8700Vol0.00
Open0.8700D1 Closing0.8700Amplitude0.00%
Mkt Cap30.72MTradable Cap24.90MTotal Shares35.31M
T/O0.00T/O Rate0.00%Tradable Shares28.62M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Open Orphan Appoints Stephen Pinkerton as CFO & Executive Director
T-Reuters  ·  2022-10-18
Open Orphan Appoints Stephen Pinkerton as CFO & Executive Director
Orphazyme A/S Anticipates A Loss From Continuing Operations In Range Of DKK 40 Million - 45 Million
T-Reuters  ·  2022-09-26
Orphazyme A/S Anticipates A Loss From Continuing Operations In Range Of DKK 40 Million - 45 Million
Open Orphan Says HY Revenue Of 18.9 Mln Stg
T-Reuters  ·  2022-09-08
Open Orphan Says HY Revenue Of 18.9 Mln Stg
Open Orphan Signs £10.4M Contract With Existing Big Pharma Client
T-Reuters  ·  2022-08-22
Open Orphan Signs £10.4M Contract With Existing Big Pharma Client
Open Orphan Signed £6.2 Mln Influenza Human Challenge Study Contract
T-Reuters  ·  2022-08-04
Open Orphan Signed £6.2 Mln Influenza Human Challenge Study Contract
Open Orphan Says Unit Signs £7.2M Rsv Human Challenge Study Contract
T-Reuters  ·  2022-06-14
Open Orphan Says Unit Signs £7.2M Rsv Human Challenge Study Contract
Open Orphan FY Revenue Rises 76%
T-Reuters  ·  2022-06-07
Open Orphan FY Revenue Rises 76%

Introduction

Company Name.
Orphazyme A/S
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Issue price:
--